https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-20 08:34:592025-11-20 08:34:59Poolbeg Pharma plc – POLB 001 European Patent granted
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-20 08:34:592025-11-20 08:34:59Poolbeg Pharma plc – POLB 001 European Patent granted
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-17 06:38:372025-11-17 06:38:37Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
https://www.optimumcomms.com/wp-content/uploads/2023/02/Medicxi_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-14 09:25:312025-11-14 09:26:45Medicxi Announces €500 Million Fund V
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-13 12:12:212025-11-13 12:12:21Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2025/09/Bluecell_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-13 08:40:102025-11-13 08:40:10Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-11 09:03:332025-11-11 09:03:33Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates 
https://www.optimumcomms.com/wp-content/uploads/2025/08/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-10 08:36:252025-11-10 08:36:25Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-07 13:09:262025-11-07 13:09:53Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-06 09:09:392025-11-06 09:09:39Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
https://www.optimumcomms.com/wp-content/uploads/2025/05/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-06 09:02:252025-11-06 09:02:25Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
https://www.optimumcomms.com/wp-content/uploads/2023/02/Amberimplants_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-06 08:37:542025-11-06 08:43:44Amber Implants Appoints Vincent Gardès as Chief Executive Officer to Drive Commercial Launch of VCFix® Spinal System
https://www.optimumcomms.com/wp-content/uploads/2025/10/AmacaThera_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-04 12:19:382025-11-04 12:19:38AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-04 07:03:172025-11-04 08:34:29Tulyp Medical emerges from Sofinnova’s medtech accelerator and announces FDA submission following initial first-in-human use
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-03 11:16:162025-11-03 11:16:30Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-31 08:15:102025-10-31 13:02:50Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
https://www.optimumcomms.com/wp-content/uploads/2024/02/Alys_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-30 08:30:452025-10-30 08:30:45Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic UrticariaWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
